Regulation of pro-protein convertase subtilisin/kexin type 9 (PCSK9) by drugs has led to the development of a still small number of agents with powerful activity on low-density lipoprotein cholesterol levels, associated with a significant reduction of cardiovascular events in patients in secondary prevention. The Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) and Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab (ODYSSEY OUTCOMES) studies, with the two available PCSK9 antagonists, i.e. evolocumab and alirocumab, both reported a 15% reduction in major adverse cardiovascular events. Regulation of PCSK9 expression is dependent upon a number of factors, partly genetic and partly associated to a complex transcriptional system, mainly controlled by sterol regulatory element binding proteins. PCSK9 is further regulated by concomitant drug treatments, particularly by statins, enhancing PCSK9 secretion but decreasing its stimulatory phosphorylated form (S688). These complex transcriptional mechanisms lead to variable circulating levels making clinical measurements of plasma PCSK9 for cardiovascular risk assessment a debated matter. Determination of total PCSK9 levels may provide a diagnostic tool for explaining an apparent resistance to PCSK9 inhibitors, thus indicating the need for other approaches. Newer agents targeting PCSK9 are in clinical development with a major interest in those with a longer duration of action, e.g. RNA silencing, allowing optimal patient compliance. Interest has been expanded to areas not only limited to low-density lipoprotein cholesterol reduction but also investigating other non-lipid pathways raising cardiovascular risk, in particular inflammation associated to raised high-sensitivity C-reactive protein levels, not significantly affected by the present PCSK9 antagonists.
FerenceBAGinsbergHNGrahamIet al.Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J2017; 38: 2459–2472.
2.
Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R et al. Efficacy and safety of LDL-lowering therapy among men and women: Meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet2015; 385: 1397–1405.
3.
SabatineMSWiviottSDImKet al.Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: A meta-analysis. JAMA Cardiol2018; 3: 823–828. .
4.
Koenig W, Giovas P and Nicholls SJ. Combining cholesterol-lowering strategies with imaging data: A visible benefit? Eur J Prev Cardiol. 2019; 26: 365–379.
5.
FerenceBAGrahamITokgozogluLet al.Impact of lipids on cardiovascular health: JACC Health Promotion Series. J Am Coll Cardiol2018; 72: 1141–1156.
6.
De BackerGG. Prevention of cardiovascular disease: Much more is needed. Eur J Prev Cardiol2018; 25: 1083–1086.
7.
CohenJCBoerwinkleEMosleyTHJret al.Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med2006; 354: 1264–1272.
8.
Myocardial Infarction GeneticsCKathiresanSVoightBFet al.Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet2009; 41: 334–341. .
9.
AbifadelMVarretMRabesJPet al.Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet2003; 34: 154–156.
10.
RosensonRSHegeleRAFazioSet al.The evolving future of PCSK9 inhibitors. J Am Coll Cardiol2018; 72: 314–329.
11.
ChengJMOemrawsinghRMGarcia-GarciaHMet al.PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. Atherosclerosis2016; 248: 117–122.
12.
FerriNMarchianoSTibollaGet al.PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Atherosclerosis2016; 253: 214–224.
13.
LeeCJLeeYHParkSWet al.Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism2013; 62: 845–850.
14.
RuscicaMFerriNFogacciFet al.Circulating levels of proprotein convertase subtilisin/kexin type 9 and arterial stiffness in a large population sample: Data from the Brisighella Heart Study. J Am Heart Assoc2017; 6: e005764.
15.
RuscicaMFerriNMacchiCet al.Liver fat accumulation is associated with circulating PCSK9. Ann Med2016; 48: 384–391.
GiunzioniITavoriHCovarrubiasRet al.Local effects of human PCSK9 on the atherosclerotic lesion. J Pathol2016; 238: 52–62.
18.
CameraMRossettiLBarbieriSSet al.PCSK9 as a positive modulator of platelet activation. J Am Coll Cardiol2018; 71: 952–954.
19.
RicciCRuscicaMCameraMet al.PCSK9 induces a pro-inflammatory response in macrophages. Sci Rep2018; 8: 2267.
20.
PoggioPSongiaPCavallottiLet al.PCSK9 involvement in aortic valve calcification. J Am Coll Cardiol2018; 72: 3225–3227.
21.
SeidahNGChretienMMbikayM. The ever-expanding saga of the proprotein convertases and their roles in body homeostasis: Emphasis on novel proprotein convertase subtilisin kexin number 9 functions and regulation. Curr Opin Lipidol2018; 29: 144–150.
22.
LakoskiSGLagaceTACohenJCet al.Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab2009; 94: 2537–2543.
PerssonLCaoGStahleLet al.Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans. Arterioscler Thromb Vasc Biol2010; 30: 2666–2672.
25.
ArtensteinAWOpalSM. Proprotein convertases in health and disease. N Engl J Med2011; 365: 2507–2518.
26.
SeidahNGMayerGZaidAet al.The activation and physiological functions of the proprotein convertases. Int J Biochem Cell Biol2008; 40: 1111–1125.
27.
SeidahNGPratA. The biology and therapeutic targeting of the proprotein convertases. Nat Rev Drug Discov2012; 11: 367–383.
28.
ZhangDWLagaceTAGarutiRet al.Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem2007; 282: 18602–18612.
29.
MayneJDewpuraTRaymondAet al.Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture. Clin Chem2011; 57: 1415–1423.
30.
BenjannetSHamelinJChretienMet al.Loss- and gain-of-function PCSK9 variants: Cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem2012; 287: 33745–33755.
31.
CunninghamDDanleyDEGeogheganKFet al.Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol2007; 14: 413–419.
32.
PiperDEJacksonSLiuQet al.The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol. Structure2007; 15: 545–552.
33.
ZhaoZTuakli-WosornuYLagaceTAet al.Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet2006; 79: 514–523.
34.
CariouBOuguerramKZairYet al.PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol2009; 29: 2191–2197.
35.
YamamotoTLuCRyanRO. A two-step binding model of PCSK9 interaction with the low density lipoprotein receptor. J Biol Chem2011; 286: 5464–5470.
36.
EssalmaniRSusan-ResigaDChamberlandAet al.In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem2011; 286: 4257–4263.
37.
GauthierMSAwanZBouchardAet al.Posttranslational modification of proprotein convertase subtilisin/kexin type 9 is differentially regulated in response to distinct cardiometabolic treatments as revealed by targeted proteomics. J Clin Lipidol2018; 12: 1027–1038.
38.
TavoriHGiunzioniILintonMFet al.Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis. Circ Res2013; 113: 1290–1295.
39.
ShapiroMDTavoriHFazioS. PCSK9: From basic science discoveries to clinical trials. Circ Res2018; 122: 1420–1438.
40.
RomagnuoloRScipioneCABoffaMBet al.Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem2015; 290: 11649–11662.
41.
VineyNJYeangCYangXet al.Relationship between ‘LDL-C’, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. J Clin Lipidol2018; 12: 702–710.
42.
FerriNCorsiniAMacchiCet al.Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: Experimental animal models and clinical evidence. Transl Res2016; 173: 19–29.
43.
RuscicaMSimonelliSBottaMet al.Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Biochim Biophys Acta2018; 1863: 991–997.
44.
SeidahNGBenjannetSWickhamLet al.The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A2003; 100: 928–933.
45.
HortonJDShahNAWarringtonJAet al.Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci U S A2003; 100: 12027–12032.
46.
HortonJDGoldsteinJLBrownMS. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest2002; 109: 1125–1131.
47.
BennettMKTothJIOsborneTF. Selective association of sterol regulatory element-binding protein isoforms with target promoters in vivo. J Biol Chem2004; 279: 37360–37367.
48.
SunLPLiLGoldsteinJLet al.Insig required for sterol-mediated inhibition of Scap/SREBP binding to COPII proteins in vitro. J Biol Chem2005; 280: 26483–26490.
49.
ShaoWEspenshadePJ. Sterol regulatory element-binding protein (SREBP) cleavage regulates Golgi-to-endoplasmic reticulum recycling of SREBP cleavage-activating protein (SCAP). J Biol Chem2014; 289: 7547–7557.
50.
DubucGChamberlandAWassefHet al.Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol2004; 24: 1454–1459.
51.
PramfalkCJiangZYCaiQet al.HNF1alpha and SREBP2 are important regulators of NPC1L1 in human liver. J Lipid Res2010; 51: 1354–1362.
52.
ShendeVRWuMSinghABet al.Reduction of circulating PCSK9 and LDL-C levels by liver-specific knockdown of HNF1alpha in normolipidemic mice. J Lipid Res2015; 56: 801–809.
53.
RuscicaMRicciCMacchiCet al.Suppressor of cytokine signaling-3 (SOCS-3) induces proprotein convertase subtilisin kexin type 9 (PCSK9) expression in hepatic HepG2 cell line. J Biol Chem2016; 291: 3508–3519.
54.
LiHDongBParkSWet al.Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine. J Biol Chem2009; 284: 28885–28895.
55.
LiHLiuJ. The novel function of HINFP as a co-activator in sterol-regulated transcription of PCSK9 in HepG2 cells. Biochem J2012; 443: 757–768.
56.
TaoRXiongXDePinhoRAet al.FoxO3 transcription factor and Sirt6 deacetylase regulate low density lipoprotein (LDL)-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression. J Biol Chem2013; 288: 29252–29259.
57.
PoirierSSamamiSMamarbachiMet al.The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolism. J Biol Chem2014; 289: 18736–18751.
58.
NaeliPMirzadeh AzadFMalakootianMet al.Post-transcriptional regulation of PCSK9 by miR-191, miR-222, and miR-224. Front Genet2017; 8: 189.
59.
ReinerZ. Statins in the primary prevention of cardiovascular disease. Nat Rev Cardiol2013; 10: 453–464.
60.
HobbsFDBanachMMikhailidisDPet al.Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate. BMC Med2016; 14: 4.
61.
DongBWuMLiHet al.Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. J Lipid Res2010; 51: 1486–1495.
62.
DongBSinghABShendeVRet al.Hepatic HNF1 transcription factors control the induction of PCSK9 mediated by rosuvastatin in normolipidemic hamsters. Int J Mol Med2017; 39: 749–756.
SahebkarASimental-MendiaLEGuerrero-RomeroFet al.Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: A systematic review and meta-analysis of clinical trials. Diabetes Obes Metab2015; 17: 1042–1055.
65.
GuoYLLiuJXuRXet al.Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9. Clin Drug Investig2013; 33: 877–883.
66.
CareskeyHEDavisRAAlbornWEet al.Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9. J Lipid Res2008; 49: 394–398.
67.
TremblayAJLamarcheBLemelinVet al.Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J Lipid Res2011; 52: 558–565.
68.
WelderGZinehIPacanowskiMAet al.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol. J Lipid Res2010; 51: 2714–2721.
69.
ZhangJLongMYuY. The effects of additional ezetimibe treatment to baseline rosuvastatin on circulating PCSK9 among patients with stable angina. J Thorac Dis2017; 9: 1226–1233.
70.
DubucGTremblayMPareGet al.A new method for measurement of total plasma PCSK9: Clinical applications. J Lipid Res2010; 51: 140–149.
71.
RaalFPanzVImmelmanAet al.Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc2013; 2: e000028.
72.
BertholdHKSeidahNGBenjannetSet al.Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. PLoS One2013; 8: e60095.
73.
ChenFMaridakisVO'NeillEAet al.The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia. Biomarkers2011; 16: 321–333.
74.
LakoskiSGXuFVegaGLet al.Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab2010; 95: 800–809.
75.
FerriNMarchianoSLupoMGet al.Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: Role of the small G protein Rac1. Pharmacol Res2017; 122: 96–104.
76.
NozueTHattoriHIshiharaMet al.Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin/kexin type 9 levels in statin-naive patients with coronary artery disease. Am J Cardiol2013; 111: 1415–1419.
77.
TelfordDESutherlandBGEdwardsJYet al.The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J Lipid Res2007; 48: 699–708.
78.
MiyoshiTNakamuraKDoiMet al.Impact of ezetimibe alone or in addition to a statin on plasma PCSK9 concentrations in patients with type 2 diabetes and hypercholesterolemia: A pilot study. Am J Cardiovasc Drugs2015; 15: 213–219.
79.
DavignonJDubucG. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels. Trans Am Clin Climatol Assoc2009; 120: 163–173.
80.
CohenJCPertsemlidisAFahmiSet al.Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. Proc Natl Acad Sci U S A2006; 103: 1810–1815.
81.
SilbernagelGSteinerLKHollsteinTet al.The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption. J Lipid Res2019; 60: 161–167.
82.
FerriNCorsiniASirtoriCet al.PPAR-alpha agonists are still on the rise: An update on clinical and experimental findings. Expert Opin Investig Drugs2017; 26: 593–602.
83.
PostSMDuezHGervoisPPet al.Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol2001; 21: 1840–1845.
84.
LambertGJarnouxALPineauTet al.Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: Lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor. Endocrinology2006; 147: 4985–4995.
85.
MayneJDewpuraTRaymondAet al.Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis2008; 7: 22.
86.
TrouttJSAlbornWECaoGet al.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels. J Lipid Res2010; 51: 345–351.
87.
LambertGAncellinNCharltonFet al.Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment. Clin Chem2008; 54: 1038–1045.
88.
NoguchiTKobayashiJYagiKet al.Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study. Atherosclerosis2011; 217: 165–170.
89.
CostetPHoffmannMMCariouBet al.Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis2010; 212: 246–251.
90.
ChanDCHamiltonSJRyeKAet al.Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Diabetes Obes Metab2010; 12: 752–756.
91.
BrewerHB. Comparative evaluation of fibric acid derivatives and HMG-CoA reductase inhibitors. Atherosclerosis1992; 97: S11–S19.
92.
KourimateSLe MayCLanghiCet al.Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9. J Biol Chem2008; 283: 9666–9673.
93.
SirtoriCRGalliCFranceschiniG. Fraudulent (and non fraudulent) fatty acids for human health. Eur J Clin Invest1993; 23: 686–689.
94.
BottaMAudanoMSahebkarAet al.PPAR agonists and metabolic syndrome: An established role?. Int J Mol Sci2018; 19: e1197.
95.
CostetPCariouBLambertGet al.Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. J Biol Chem2006; 281: 6211–6218.
ZimmerMBistaPBensonELet al.CAT-2003: A novel sterol regulatory element-binding protein inhibitor that reduces steatohepatitis, plasma lipids, and atherosclerosis in apolipoprotein E*3-Leiden mice. Hepatol Commun2017; 1: 311–325.
98.
GraversenCBLundbye-ChristensenSThomsenBet al.Marine n-3 polyunsaturated fatty acids lower plasma proprotein convertase subtilisin kexin type 9 levels in pre- and postmenopausal women: A randomised study. Vascul Pharmacol2016; 76: 37–41.
99.
FerriNCorsiniASirtoriCRet al.Present therapeutic role of cholesteryl ester transfer protein inhibitors. Pharmacol Res2018; 128: 29–41.
100.
MillarJSReyes-SofferGJumesPet al.Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest2015; 125: 2510–2522.
101.
GironaJIbarretxeDPlanaNet al.Circulating PCSK9 levels and CETP plasma activity are independently associated in patients with metabolic diseases. Cardiovasc Diabetol2016; 15: 107.
102.
ArsenaultBJPetridesFTabetFet al.Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. J Clin Lipidol2018; 12: 130–136.
103.
KheraAVQamarAReillyMPet al.Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia. Am J Cardiol2015; 115: 178–182.
104.
PoliABarbagalloCMCiceroAFGet al.Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. Pharmacol Res2018; 134: 51–60.
105.
MomtaziAABanachMPirroMet al.Regulation of PCSK9 by nutraceuticals. Pharmacol Res2017; 120: 157–169.
106.
JohnstonTPKorolenkoTAPirroMet al.Preventing cardiovascular heart disease: Promising nutraceutical and non-nutraceutical treatments for cholesterol management. Pharmacol Res2017; 120: 219–225.
107.
KongWWeiJAbidiPet al.Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med2004; 10: 1344–1351.
DongBLiHSinghABet al.Inhibition of PCSK9 transcription by berberine involves down-regulation of hepatic HNF1alpha protein expression through the ubiquitin-proteasome degradation pathway. J Biol Chem2015; 290: 4047–4058.
110.
PisciottaLBellocchioABertoliniS. Nutraceutical pill containing berberine versus ezetimibe on plasma lipid pattern in hypercholesterolemic subjects and its additive effect in patients with familial hypercholesterolemia on stable cholesterol-lowering treatment. Lipids Health Dis2012; 11: 123.
111.
RuscicaMGomaraschiMMombelliGet al.Nutraceutical approach to moderate cardiometabolic risk: Results of a randomized, double-blind and crossover study with Armolipid Plus. J Clin Lipidol2014; 8: 61–68.
112.
BanachMPattiAMGiglioRVet al.The role of nutraceuticals in statin intolerant patients. J Am Coll Cardiol2018; 72: 96–118.
113.
ZhangYLiuJLiSet al.Impact of currently prescribed lipid-lowering drugs on plasma PCSK9 concentration: Single or in combination study in rats. Lipids Health Dis2014; 13: 35.
114.
AdorniMPFerriNMarchianoSet al.Effect of a novel nutraceutical combination on serum lipoprotein functional profile and circulating PCSK9. Ther Clin Risk Manag2017; 13: 1555–1562.
115.
SpigoniVAldigeriRAntoniniMet al.Effects of a New nutraceutical formulation (berberine, red yeast rice and chitosan) on non-HDL cholesterol levels in individuals with dyslipidemia: Results from a randomized, double blind, placebo-controlled study. Int J Mol Sci2017; 18: e1498.
116.
FerriNCorsiniASirtoriCRet al.Bococizumab for the treatment of hypercholesterolaemia. Expert Opin Biol Ther2017; 17: 237–243.
117.
FerriNCorsiniASirtoriCRet al.Bococizumab for the treatment of hypercholesterolaemia. Expert Opin Biol Ther2017; 17: 909–910. .
118.
KasichayanulaSGroverAEmeryMGet al.Clinical pharmacokinetics and pharmacodynamics of evolocumab, a PCSK9 inhibitor. Clin Pharmacokinet2018; 57: 769–779.
119.
FarnierM. An evaluation of alirocumab for the treatment of hypercholesterolemia. Expert Rev Cardiovasc Ther2015; 13: 1307–1323.
120.
PecinIHartgersMLHovinghGKet al.Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. Eur J Prev Cardiol2017; 24: 1383–1401.
121.
RobinsonJGHuijgenRRayKet al.Determining when to add nonstatin therapy: A quantitative approach. J Am Coll Cardiol2016; 68: 2412–2421.
122.
LandmesserUChapmanMJStockJKet al.2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J2018; 39: 1131–1143.
123.
SabatineMSGiuglianoRPKeechACet al.Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med2017; 376: 1713–1722.
124.
O'Donoghue ML, Fazio S, Giugliano RP, et al. Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: Insights from the FOURIER Trial. Circulation. Epub ahead of print 30 November 2018. DOI: 10.1161/CIRCULATIONAHA.118.037184.
125.
SabatineMSLeiterLAWiviottSDet al.Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: A prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol2017; 5: 941–950.
126.
Sabatine MS, De Ferrari GM, Giugliano RP, et al. Clinical benefit of evolocumab by severity and extent of coronary artery disease: An analysis from FOURIER. Circulation2018; 138(8): 756–766. DOI: 10.1161/CIRCULATIONAHA.118.034309.
127.
BonacaMPNaultPGiuglianoRPet al.Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). Circulation2018; 137: 338–350.
128.
GiuglianoRPMachFZavitzKet al.Cognitive function in a randomized trial of evolocumab. N Engl J Med2017; 377: 633–643.
129.
NichollsSJPuriRAndersonTet al.Effect of evolocumab on progression of coronary disease in statin-treated patients: The GLAGOV randomized clinical trial. JAMA2016; 316: 2373–2384.
130.
NichollsSJPuriRAndersonTet al.Effect of evolocumab on coronary plaque composition. J Am Coll Cardiol2018; 72: 2012–2021.
131.
Wilson PWF, Polonsky TS, Miedema MD, et al. Systematic review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol2018; pii: S0735-1097(18)39035-1. DOI: 10.1016/j.jacc.2018.11.004.
132.
SchwartzGGStegPGSzarekMet al.Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med2018; 379: 2097–2107. .
133.
Szarek M, White HD, Schwartz GG, et al. Alirocumab reduces total nonfatal cardiovascular and fatal events in the ODYSSEY OUTCOMES trial. J Am Coll Cardiol2019; 73: 387–396. DOI: 10.1016/j.jacc.2018.10.039.
134.
HadjiphilippouSRayKK. PCSK9 inhibition and atherosclerotic cardiovascular disease prevention: Does reality match the hype?. Heart2017; 103: 1670–1679.
135.
Otake H, Sugizaki Y, Toba T, et al. Efficacy of alirocumab for reducing plaque vulnerability: Study protocol for ALTAIR, a randomized controlled trial in Japanese patients with coronary artery disease receiving rosuvastatin. J Cardiol2018; pii: S0914-5087(18)30340-X. DOI: 10.1016/j.jjcc.2018.11.012.
136.
KereiakesDJLeporNEGerberRet al.Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials. Atherosclerosis2018; 277: 211–218. .
137.
LeiterLATinahonesFJKaralisDGet al.Alirocumab safety in people with and without diabetes mellitus: Pooled data from 14 ODYSSEY trials. Diabet Med2018; 35: 1742–1751.
138.
TaskinenMRDel PratoSBujas-BobanovicMet al.Efficacy and safety of alirocumab in individuals with type 2 diabetes mellitus with or without mixed dyslipidaemia: Analysis of the ODYSSEY LONG TERM trial. Atherosclerosis2018; 276: 124–130.
139.
KhvorovaA. Oligonucleotide therapeutics – a new class of cholesterol-lowering drugs. N Engl J Med2017; 376: 4–7.
140.
FitzgeraldKFrank-KamenetskyMShulga-MorskayaSet al.Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, placebo-controlled, phase 1 trial. Lancet2014; 383: 60–68.
141.
FitzgeraldKWhiteSBorodovskyAet al.A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med2017; 376: 41–51.
142.
RayKKLandmesserULeiterLAet al.Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med2017; 376: 1430–1440.
143.
LeiterLATeohHKallendDet al.Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: The ORION-1 randomized clinical trial. Diabetes Care2018; 42: 173–176. .
144.
RayKKStoekenbroekRMKallendDet al.Effect of an siRNA therapeutic targeting PCSK9 on atherogenic lipoproteins: Pre-specified secondary end points in ORION 1. Circulation2018; 138: 1304–1316. .
145.
WernerCHoffmannMMWinklerKet al.Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol2014; 62: 94–102.
146.
ZhuYMAndersonTJSikdarKet al.Association of proprotein convertase subtilisin/kexin type 9 (PCSK9) with cardiovascular risk in primary prevention. Arterioscler Thromb Vasc Biol2015; 35: 2254–2259.
147.
RidkerPMRifaiNBradwinGet al.Plasma proprotein convertase subtilisin/kexin type 9 levels and the risk of first cardiovascular events. Eur Heart J2016; 37: 554–560.
148.
GencerBMontecuccoFNanchenDet al.Prognostic value of PCSK9 levels in patients with acute coronary syndromes. Eur Heart J2016; 37: 546–553.
149.
VlachopoulosCTerentes-PrintziosDGeorgiopoulosGet al.Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. Atherosclerosis2016; 252: 50–60.
150.
PottJSchlegelVTerenAet al.Genetic regulation of PCSK9 (proprotein convertase subtilisin/kexin type 9) plasma levels and its impact on atherosclerotic vascular disease phenotypes. Circ Genom Precis Med2018; 11: e001992.
151.
Macchi C, Ferri N, Favero C, et al. Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals. Eur J Prev Cardiol. 2019; 26: 578–588.
152.
FerriNRuscicaM. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: Insights on insulin resistance, inflammation, and atherogenic dyslipidemia. Endocrine2016; 54: 588–601.
153.
El KhouryPRousselRFumeronFet al.Plasma proprotein-convertase-subtilisin/kexin type 9 (PCSK9) and cardiovascular events in type 2 diabetes. Diabetes Obes Metab2018; 20: 943–953.
154.
KhanSUTalluriSRiazHet al.A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. Eur J Prev Cardiol2018; 25: 844–853.
155.
ShapiroMDMilesJTavoriHet al.Diagnosing resistance to a proprotein convertase subtilisin/kexin type 9 inhibitor. Ann Intern Med2018; 168: 376–379.
156.
DesaiNRGiuglianoRPWassermanSMet al.Association between circulating baseline proprotein convertase subtilisin kexin type 9 levels and efficacy of evolocumab. JAMA Cardiol2017; 2: 556–560.
157.
ReinerZ. PCSK9 inhibitors in clinical practice: Expectations and reality. Atherosclerosis2018; 270: 187–188.
158.
Grundy S, Stone N, Bailey A, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. Epub before print 10 November 2018. DOI: 10.1161/CIR.0000000000000625.
159.
ViraniSAkeroydJNambiVet al.Applicability and cost implications for PCKS9 inhibitors based on the ODYSSEY OUTCOMES trial: Insights from the Department of Veterans Affairs. Circulation2018; 139: 410–412. .
160.
TunonJBackMBadimonLet al.Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. Eur J Prev Cardiol2018; 25: 948–955.
161.
RuscicaMFerriNCorsiniAet al.PCSK9 antagonists and inflammation. Atherosclerosis2018; 268: 235–236.
162.
RuscicaMFerriNMacchiCet al.Lipid lowering drugs and inflammatory changes: An impact on cardiovascular outcomes?. Ann Med2018; 50: 461–484.
163.
SlizEKettunenJHolmesMVet al.Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment. Circulation2018; 138: 2499–2512.
164.
KianoushSBittencourtMSLotufoPAet al.Association between smoking and serum GlycA and high-sensitivity C-reactive protein levels: The Multi-Ethnic Study of Atherosclerosis (MESA) and Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). J Am Heart Assoc2017; 6(8): pii: e006545 DOI: 10.1161/JAHA.117.006545.
165.
ZentiMGAltomariALupoMGet al.From lipoprotein apheresis to proprotein convertase subtilisin/kexin type 9 inhibitors: Impact on low-density lipoprotein cholesterol and C-reactive protein levels in cardiovascular disease patients. Eur J Prev Cardiol2018; 25: 1843–1851. .
166.
BohulaEAGiuglianoRPLeiterLAet al.Inflammatory and cholesterol risk in the FOURIER trial. Circulation2018; 138: 131–140.
167.
KhademiFMomtazi-BorojeniAAReinerZet al.PCSK9 and infection: A potentially useful or dangerous association?. J Cell Physiol2018; 233: 2920–2927.
168.
NishikidoTRayKK. Inclisiran for the treatment of dyslipidemia. Expert Opin Investig Drugs2018; 27: 287–294.
169.
ColhounHMGinsbergHNRobinsonJGet al.No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J2016; 37: 2981–2989.
170.
FerenceBARobinsonJGBrookRDet al.Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med2016; 375: 2144–2153.
171.
LottaLASharpSJBurgessSet al.Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: A meta-analysis. JAMA2016; 316: 1383–1391.
172.
SchmidtAFSwerdlowDIHolmesMVet al.PCSK9 genetic variants and risk of type 2 diabetes: A Mendelian randomisation study. Lancet Diabetes Endocrinol2017; 5: 97–105.
173.
Da DaltLRuscicaMBonacinaFet al.PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: The role of the low-density lipoprotein receptor. Eur Heart J2018; 40: 357–368. .
174.
PaneniFCostantinoS. PCSK9 in diabetes: Sweet, bitter or sour?. Eur Heart J2018; 40: 369–371. .
175.
AbifadelMElbitarSEl KhouryPet al.Living the PCSK9 adventure: From the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. Curr Atheroscler Rep2014; 16: 439.
176.
KonradRJTrouttJSCaoG. Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents. Lipids Health Dis2011; 10: 38.
